Welcome to our dedicated page for IDEX SEC filings (Ticker: IEX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to IDEX Corporation (NYSE: IEX) SEC filings, offering investors a primary source of regulatory information about the global engineered products company. IDEX files a variety of documents with the U.S. Securities and Exchange Commission that detail its financial performance, segment results, capital allocation decisions and governance matters.
Through Forms 10-K and 10-Q, investors can review consolidated and segment-level data for the Health & Science Technologies, Fluid & Metering Technologies, and Fire & Safety / Diversified Products segments, along with discussions of pricing, volume trends, acquisitions and non-GAAP measures such as organic sales, adjusted EBITDA and free cash flow. Current reports on Form 8-K, several of which are reflected in the recent filings list, disclose material events including quarterly earnings announcements, changes in executive leadership, and share repurchase authorizations.
Filings also identify IDEX’s common stock listing on the New York Stock Exchange under the symbol IEX and provide details on items such as dividend declarations, capital structure and certain compensation arrangements for senior executives. For those monitoring insider activity, Forms 3, 4 and 5 (when available) show transactions by directors and officers in IDEX equity.
On Stock Titan, these documents are supplemented with AI-powered summaries that highlight key points from lengthy filings, helping readers quickly understand segment performance, major risks, capital deployment and notable governance changes. Real-time updates from EDGAR ensure that new IDEX filings, from quarterly reports to event-driven 8-Ks, appear promptly, giving investors and researchers an efficient way to follow the regulatory record behind IEX stock.
IDEX Corporation (IEX) reported higher quarterly results. For the three months ended September 30, 2025, net sales were $878.7 million, up from $798.2 million, with operating income of $185.8 million versus $168.0 million. Diluted EPS was $1.70 compared with $1.57 a year ago.
Nine-month results were mixed: net sales rose to $2,558.4 million from $2,405.9 million, while net income attributable to IDEX was $354.9 million versus $381.8 million, and diluted EPS was $4.70 versus $5.02. Operating cash flow reached $470.9 million. The company repurchased $175.0 million of common stock year to date and declared a quarterly dividend of $0.71 per share.
Health & Science Technologies led growth, with Q3 revenue of $380.1 million (from $309.9 million), aided by acquisitions. IDEX completed the acquisition of Micro‑LAM for total consideration of $81.9 million and ended the quarter with cash and cash equivalents of $593.8 million and total borrowings of $1,911.8 million, including $310.6 million drawn on its revolving facility.
IDEX Corporation furnished an Item 2.02 Form 8‑K announcing quarterly results for the period ended September 30, 2025. The company issued a press release, provided as Exhibit 99.1, on October 29, 2025. This information is being furnished and is not deemed filed under the Exchange Act. The filing also lists Exhibit 104 for the cover page Inline XBRL tags.
IDEX Corporation disclosed that its Board of Directors authorized an additional $635 million for repurchases of the company’s common shares. When combined with approximately $365 million remaining under prior authorizations, the company now has a total share repurchase authorization of about $1 billion.
The company states that repurchases may occur from time to time through open market or privately negotiated transactions and may also be executed under Rule 10b5-1 plans. Management will determine the timing, volume and nature of repurchases based on market conditions, cash investment priorities, applicable securities laws and other factors, and the program can be suspended or discontinued at any time.
Helmkamp Katrina L, identified as a director of IDEX Corporation (IEX), purchased 2,500 shares of common stock on 08/07/2025 at a weighted average price of $159.6104 per share, in multiple trades priced between $159.51 and $159.65. After the reported acquisition, the reporting person beneficially owns 13,200 shares directly.
The Form 4 shows no derivative transactions in Table II. A footnote states the transaction was executed in multiple trades and that the reporting person will provide detailed per-trade quantities and prices upon request.